keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophagic junction cancer

keyword
https://www.readbyqxmd.com/read/28917586/dosimetric-comparison-to-the-heart-and-cardiac-substructure-in-a-large-cohort-of-esophageal-cancer-patients-treated-with-proton-beam-therapy-or-intensity-modulated-radiation-therapy
#1
Yutaka Shiraishi, Cai Xu, Jinzhong Yang, Ritsuko Komaki, Steven H Lin
PURPOSE: To compare heart and cardiac substructure radiation exposure using intensity-modulated radiotherapy (IMRT) vs. proton beam therapy (PBT) for patients with mid- to distal esophageal cancer who received chemoradiation therapy. METHODS AND MATERIALS: We identified 727 esophageal cancer patients who received IMRT (n=477) or PBT (n=250) from March 2004 to December 2015. All patients were treated to 50.4Gy with IMRT or to 50.4 cobalt Gray equivalents with PBT...
September 13, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28911091/a-phase-iii-trial-comparing-oral-s-1-cisplatin-and-intravenous-5-fluorouracil-cisplatin-in-patients-with-untreated-diffuse-gastric-cancer
#2
J A Ajani, M Abramov, I Bondarenko, Y Shparyk, V Gorbunova, A Hontsa, N Otchenash, M Alsina, S Lazarev, J Feliu, A Elme, V Esko, K Abdalla, U Verma, F Benedetti, T Aoyama, H Mizuguchi, L Makris, G Rosati
Background: The effect of histology-based treatment regimen on diffuse gastric adenocarcinoma has not been evaluated in clinical trials. This international phase III trial evaluated the efficacy and safety of S-1 (a contemporary oral fluoropyrimidine)/cisplatin versus 5-fluorouracil (5-FU)/cisplatin in chemotherapy-naïve patients with diffuse-type adenocarcinoma involving the gastroesophageal junction or stomach. Patients and methods: Eligibility criteria included untreated, measurable, advanced diffuse adenocarcinoma confirmed by central pathology and performance status of 0-1...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28900499/profiling-chemotherapy-associated-myelotoxicity-among-chinese-gastric-cancer-population-receiving-cytotoxic-conventional-regimens-epidemiological-features-timing-predictors-and-clinical-impacts
#3
Ci Zhu, Yan Wang, Xicheng Wang, Chunmei Bai, Dan Su, Bing Cao, Jianming Xu
Objectives: We aim to evaluate the epidemiological features, timing, predictors and clinical impacts of chemotherapy-associated myelotoxicity in Chinese gastric cancer population receiving six established cytotoxic conventional regimens (CF/XP, EC(O)F/EC(O)X, DC(O)F/DC(O)X, PC(O)F/PC(O)X, FOLFOX4, or mFOLFOX7/XELOX). Patients and methods: A 4-year multicenter, prospective, observational study was conducted in multiple hospitals/institutes spanning three major regions in China. A total of 1,285 patients with gastric cancer, treated with six selected regimens between 2010 and 2014 were included...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28895419/role-of-obesity-and-abdominal-shape-morphometric-features-to-predict-postoperative-complications-and-quality-of-lymph-node-dissection-of-gastrectomy-for-gastric-cancer
#4
M HasbahcecI, E MehdI, F U Malya, E Kunduz, N MemmI, S YIgman, A Akcakaya
Obesity and abdominal shape morphometric features have been thought to be independent risk factors for surgical outcomes after gastrectomy.A total of 113 patients undergoing surgery for primary gastric adenocarcinoma from June 2011 to January 2015 were retrospectively included. Body mass index, visceral fatty area, anterior-posterior abdominal and transverse diameters and depth ratio at levels of the umbilicus, the gastroesophageal junction and the root of the celiac artery were measured or calculated. Patients were grouped according to body mass index (<25...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28881884/clinical-outcomes-and-benefits-for-staging-of-surgical-lymph-node-mapping-after-esophagectomy
#5
S M Lagarde, A W Phillips, M Navidi, B Disep, S M Griffin
Dissection of lymph nodes (LN) immediately after esophagectomy is utilized by some surgeons to aid determination of LN stations involved in esophageal cancer. Some suggest that this increases LN yield and gives information regarding the pattern of lymphatic spread, others feel that this may compromise a circumferential resection margin (CRM) assessment. The aim of this study is to evaluate the effect of ex vivo dissection on the assessment of the CRM and the pattern of lymph node dissemination in patients with adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) undergoing radical surgery after neoadjuvant chemotherapy and their prognostic impact...
December 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28881882/long-term-functional-outcomes-after-replacement-of-the-esophagus-with-gastric-colonic-or-jejunal-conduits-a-systematic-literature-review
#6
T Irino, A Tsekrekos, A Coppola, C M Scandavini, A Shetye, L Lundell, I Rouvelas
It is generally recognized that in patients with an intact stomach diagnosed with esophageal cancer, gastric tubulization and pull-up shall always be the preferred technique for reconstruction after an esophageal resection. However, in cases with extensive gastroesophageal junction (GEJ) cancer with aboral spread and after previous gastric surgery, alternative methods for reconstruction have to be pursued. Moreover, in benign cases as well as in those with early neoplastic lesions of the esophagus and the GEJ that are associated with long survival, it is basically unclear which conduit should be recommended...
December 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28881354/preoperative-capecitabine-oxaliplatin-and-irinotecan-in-resectable-gastric-or-gastroesophageal-junction-cancer-pathological-response-as-primary-endpoint-and-fdg-pet-predictions
#7
Rosa Berenato, Federica Morano, Filippo Pietrantonio, Christian Cotsoglou, Marta Caporale, Gabriele Infante, Alessandro Pellegrinelli, Alessandra Alessi, Carlo Battiston, Jorgelina Coppa, Barbara Padovano, Alessia Mennitto, Monica Niger, Giovanni Fucà, Silvia Lazzati, Giorgio Greco, Gabriele Delconte, Filippo de Braud, Vincenzo Mazzaferro, Maria Di Bartolomeo
OBJECTIVES: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. METHODS: Patients affected by T3-T4/N0-N+/M0 GC/GEJ cancer were treated with the COI regimen for 4 cycles followed by restaging and gastroresection with D2 lymphadenectomy. Four postoperative cycles were scheduled. The primary endpoint was pathological response rate according to Becker et al...
September 8, 2017: Oncology
https://www.readbyqxmd.com/read/28870046/-the-chinese-consensus-for-screening-diagnosis-and-management-of-barrett-s-esophagus-and-early-adenocarcinoma-2017-wanning
#8
(no author information available yet)
Patients with Barrett's esophagus (BE)/columnar lined esophagus (CLE) and adenocarcinoma are increasing, in whom 0.61% BE/CLE would develop to adenocarcinoma. The prognosis of esophageal cancer is related to the tumor stage at diagnosis. To standardize the screening, diagnosis and therapy of BE and adenocarcinoma in China, 31 digestive diseases and digestive endoscopy experts and digestive histologists drafted the consensus on the basis of clinical experience and references. The consensus defined BE as a complication of gastroesophageal reflux disease...
September 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28856802/esophagogastric-junction-cancer-successfully-treated-by-laparoscopic-proximal-gastrectomy-and-lower-esophagectomy-with-intrathoracic-double-flap-technique-a-case-report
#9
Kei Hosoda, Keishi Yamashita, Hiromitsu Moriya, Marie Washio, Hiroaki Mieno, Akira Ema, Masahiko Watanabe
A 66-year-old man was referred to our hospital for treatment of esophagogastric junction cancer. He was diagnosed as cT2N0M0, and the esophageal invasion was found to be 1 cm from the esophagogastric junction. He underwent laparoscopy-assisted proximal gastrectomy and lower esophagectomy with esophagogastrostomy using the intrathoracic double-flap technique through the transhiatal approach. The operative time was 662 min (suturing time was 198 min), and blood loss was 200 mL. The operative time was much longer for this procedure than for esophagogastrostomy with the conventional (intra-abdominal) double-flap technique...
August 30, 2017: Asian Journal of Endoscopic Surgery
https://www.readbyqxmd.com/read/28852939/health-related-quality-of-life-after-gastrectomy-esophagectomy-and-combined-esophagogastrectomy-for-gastroesophageal-junction-adenocarcinoma
#10
Joonas H Kauppila, Cecilia Ringborg, Asif Johar, Jesper Lagergren, Pernilla Lagergren
BACKGROUND: The postoperative health-related quality of life (HRQOL) outcomes in patients with gastroesophageal junction (GEJ) adenocarcinoma after gastrectomy and esophagectomy are unclear. The aim was to evaluate HRQOL outcomes 6 months after extended total gastrectomy, subtotal esophagectomy, and combined esophagogastrectomy. METHODS: Patients who underwent surgery for GEJ adenocarcinoma of Siewert type 2 or 3 in 2001-2005 were identified from a nationwide Swedish prospective and population-based cohort...
August 29, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28815080/mckeown-or-ivor-lewis-totally-minimally-invasive-esophagectomy-for-cancer-of-the-esophagus-and-gastroesophageal-junction-systematic-review-and-meta-analysis
#11
Frans van Workum, Gijs H Berkelmans, Bastiaan R Klarenbeek, Grard A P Nieuwenhuijzen, Misha D P Luyer, Camiel Rosman
BACKGROUND: Minimally invasive esophagectomy (MIE) has consistently been associated with improved perioperative outcome and similar oncological safety compared to open esophagectomy. However, it is currently unclear what type of MIE is preferred for patients with resectable esophageal cancer. METHODS: Literature was searched in Medline, Embase and the Cochrane library combining relevant search terms. Articles that included patients undergoing totally minimally invasive esophagectomy (TMIE) or hybrid minimally invasive esophagectomy (HMIE) and compared McKeown with Ivor Lewis procedures were included...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28807364/initial-results-of-the-oesophageal-and-gastric-cancer-registry-from-the-comunidad-valenciana
#12
Javier Escrig, Fernando Mingol, Roberto Martí, José Puche, Ramón Trullenque, José Antonio Barreras, Francisco Asencio, Javier Aguiló, José Manuel Navarro, Carmen Alberich, Dolores Salas, Francisco Javier Lacueva
AIMS: To evaluate the initial results of the oesophagogastric cancer registry developed for the Sociedad Valenciana de Cirugía and the Health Department of the Comunidad Valenciana (Spain). MATERIAL AND METHODS: Fourteen of the 24 public hospitals belonging to the Comunidad Valenciana participated. All patients with diagnosis of oesophageal or gastric carcinomas operated from January 2013 to December 2014 were evaluated. Demographic, clinical and pathological data were analysed...
August 11, 2017: Cirugía Española
https://www.readbyqxmd.com/read/28807249/current-trends-in-multimodality-treatment-of-esophageal-and-gastroesophageal-junction-cancer-review-article
#13
REVIEW
Fredrik Klevebro, Simon Ekman, Magnus Nilsson
PURPOSE: Multimodality treatment has now been widely introduced in the curatively intended treatment of esophageal and gastroesophageal junction cancer. We aim to give an overview of the scientific evidence for the available treatment strategies and to describe which trends that are currently developing. METHODS: We conducted a review of the scientific evidence for the different curatively intended treatment strategies that are available today. Relevant articles of randomized controlled trials, cohort studies, and meta analyses were included...
September 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28782986/her2-heterogeneity-in-gastroesophageal-cancer-detected-by-testing-biopsy-and-resection-specimens
#14
Ladan Fazlollahi, Helen E Remotti, Alina Iuga, Hui-Min Yang, Stephen M Lagana, Antonia R Sepulveda
CONTEXT: - In advanced gastric, esophageal, and gastroesophageal junction adenocarcinomas (GE-GEJ-AC) that overexpress ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2), anti-HER2 monoclonal antibody therapy confers survival benefit. To select patients for treatment, HER2 expression and gene amplification are evaluated by immunohistochemistry (IHC) and in situ hybridization. OBJECTIVE: - To determine whether GE-GEJ-AC tested for HER2 on biopsy specimens of a primary tumor show different IHC scores and/or HER2 amplification by in situ hybridization in matched resection specimens, potentially changing therapy eligibility...
August 7, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28767564/post-treatment-pre-operative-pet-response-is-not-an-independent-predictor-of-outcomes-for-patients-with-gastric-and-gej-adenocarcinoma
#15
Jonathan M Hernandez, Volkan Beylergil, Debra A Goldman, Elke van Beek, Mithat Gonen, Laura Tang, Robert Downey, Nabil Rizk, Manish Shah, Vivian Strong, Yelena Janjigian, Heiko Schöder, Daniel G Coit
OBJECTIVE: To determine whether changes in positron emission tomography (PET) avidity correlated with histologic response and were independently associated with outcome. BACKGROUND: The implications of metabolic response to neoadjuvant therapy as measured by repeat PET imaging remain ill-defined for patients with gastric and gastroesophageal junction (GEJ) cancers. METHODS: We identified patients with gastric and GEJ adenocarcinoma who were evaluated with PET imaging before and following neoadjuvant treatment, and subsequently underwent curative resections...
August 1, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28765618/lauren-subtypes-of-advanced-gastric-cancer-influence-survival-and-response-to-chemotherapy-real-world-data-from-the-agamenon-national-cancer-registry
#16
MULTICENTER STUDY
Paula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, Ana Custodio, Juana Maria Cano, Alejandra Lacalle, Isabel Echavarria, Ismael Macias, Monserrat Mangas, Laura Visa, Elvira Buxo, Felipe Álvarez Manceñido, Antonio Viudez, Carles Pericay, Aitor Azkarate, Avinash Ramchandani, Carlos López, Eva Martinez de Castro, Ana Fernández Montes, Federico Longo, Rodrigo Sánchez Bayona, Maria Luisa Limón, Asun Diaz-Serrano, Alfonso Martin Carnicero, David Arias, Paula Cerdà, Fernando Rivera, Jose Maria Vieitez, Manuel Sánchez Cánovas, M Garrido, J Gallego
BACKGROUND: The choice of chemotherapy in HER2-negative gastric cancer is based on centre's preferences and adverse effects profile. No schedule is currently accepted as standard, nor are there any factors to predict response, other than HER2 status. We seek to evaluate whether Lauren type influences the efficacy of various chemotherapies and on patient overall survival (OS). METHODS: We have conducted a multicenter study in 31 hospitals. The eligibility criteria include diagnosis of stomach or gastroesophageal junction adenocarcinoma, HER2 negativity, and chemotherapy containing 2-3 drugs...
September 5, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28736645/effect-of-helicobacter-pylori-infection-on-outcomes-in-resected-gastric-and-gastroesophageal-junction-cancer
#17
Jennifer M Kolb, Umut Ozbek, Noam Harpaz, Randall F Holcombe, Celina Ang
BACKGROUND: Helicobacter pylori (H pylori) infection is a known risk factor for gastric cancer (GC) and has been linked with gastroesophageal junction (GEJ) cancer. Studies examining the relationship between H. pylori infection, GC characteristics and prognosis are limited and have yielded conflicting results. We report on the clinicopathologic characteristics and oncologic outcomes of gastric and GEJ cancer patients with and without a history of H. pylori treated at our institution. METHODS: We retrospectively reviewed the medical records of patients over the age of 18 years who underwent curative resection for GEJ and GC at Mount Sinai Hospital between 2007 and 2012 who had histopathologic documentation of the presence or absence of H pylori infection...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28716815/exposure-response-analyses-of-ramucirumab-from-two-randomized-phase-iii-trials-of-second-line-treatment-for-advanced-gastric-or-gastroesophageal-junction-cancer
#18
Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Jaffer A Ajani, Jiri Tomasek, Howard Safran, Kumari Chandrawansa, Yanzhi Hsu, Michael Heathman, Azhar Khan, Lan Ni, Allen S Melemed, Ling Gao, David Ferry, Charles S Fuchs
Ramucirumab is an IgG1 monoclonal antibody specific for the vascular endothelial growth factor receptor-2. Ramucirumab, 8 mg/kg every two weeks, administered as monotherapy (REGARD) or in combination with paclitaxel (RAINBOW), was safe and effective in patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer. We evaluated exposure-efficacy and exposure-safety relationships of ramucirumab from two randomized, placebo-controlled phase III trials. Sparse pharmacokinetic samples were collected and a population pharmacokinetic analysis was conducted to predict ramucirumab minimum trough concentration at steady-state (Cmin,ss)...
July 17, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28712164/efficacy-and-toxicity-of-carboplatin-paclitaxel-based-chemoradiation-for-localized-oesophageal-cancer
#19
Maria Qubtia, Yasir Ishaq, Kiran Munawar, Farhana Badar, Ather Kazmi
BACKGROUND: The management of Oesophageal and Gastroesophageal junction cancers is challenging. Multimodality therapy with carboplatin/paclitaxel based chemoradiation (CRT) and surgery shows improved efficacy. In this study, we wanted to establish the efficacy and safety of CRT for neoadjuvant and radical treatment of localized oesophageal cancer. METHODS: Patients with oesophageal cancer, registered between September 2013 and October 2014 were reviewed retrospectively...
January 2017: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28680718/prognostic-factor-analysis-of-overall-survival-in-gastric-cancer-from-two-phase-iii-studies-of-second-line-ramucirumab-regard-and-rainbow-using-pooled-patient-data
#20
Charles S Fuchs, Kei Muro, Jiri Tomasek, Eric Van Cutsem, Jae Yong Cho, Sang-Cheul Oh, Howard Safran, György Bodoky, Ian Chau, Yasuhiro Shimada, Salah-Eddin Al-Batran, Rodolfo Passalacqua, Atsushi Ohtsu, Michael Emig, David Ferry, Kumari Chandrawansa, Yanzhi Hsu, Andreas Sashegyi, Astra M Liepa, Hansjochen Wilke
PURPOSE: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. MATERIALS AND METHODS: We pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW)...
June 2017: Journal of Gastric Cancer
keyword
keyword
110187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"